The HBP1 protein as a candidate vaccine for meningococcal disease.
In order to cause serious disease, meningococcal bacteria need to be able to move from the back of the throat into the bloodstream and spread around the body. These bacteria need iron to survive, and in the bloodstream the source of iron is either heme or haemoglobin. The researchers have identified a protein produced by meningococcal bacteria that allows them to use these sources of iron in the bloodstream. The protein is called heme binding protein 1 (HBP1). Earlier experiments have indicated that this protein may be useful in a vaccine to protect against meningococcal disease.
What the research team did
The researchers first checked to see whether most meningococcal bacteria actually have the gene that makes HBP1 and found that they all do, but some make a slightly different version. They prepared samples of these different versions and found that antibodies raised against one HBP1 version were able to recognise all the different versions tested. They also found that the antibodies were able to activate components of human blood, allowing killing of the meningococcal bacteria.
Summary and impact of results
The results of this project could lead to the development of a vaccine offering broader protection against meningococcal disease and could also be applied to protection against other infectious diseases.
The project was completed in November 2013 and the researchers are keen to continue the investigation of this potential vaccine candidate. They have filed a patent application and are in discussion with the venture capital sector.